Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Sunobinop

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sunobinop Ph 1B Data in Interstitial Cystitis/Pain Syndrome Out
    Sunobinop Ph 1B Data in Interstitial Cystitis/Pain Syndrome Out

    09 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250908639413/en/Results-From-Sunobinop-Phase-1B-Study-in-Patients-With-Interstitial-CystitisBladder-Pain-Syndrome-Announced

    BUSINESSWIRE
    09 Sep 2025
    Share Share
    Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial
    Imbrium Therapeutics Achieves Last Patient Last Visit in Clinical Trial

    11 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250311007864/en

    BUSINESSWIRE
    11 Mar 2025
    Share Share
    Imbrium Phase 1b Data For Sunobinop In Overactive Bladder Syndrome
    Imbrium Phase 1b Data For Sunobinop In Overactive Bladder Syndrome

    07 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250107207362/en

    BUSINESSWIRE
    07 Jan 2025
    Share Share